Did consumption of flour bleached by the agene process contribute to the incidence of neurological disease?

Medical Hypotheses

Volumn 51, Issue 6, 1998, Pages 477-481

  Shaw, C A ^a   Bains, J S ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIA; ANTIOXIDANT; GLUTAMINE; GLUTATHIONE; METHIONINE SULFOXIMINE; SCAVENGER;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; FLOUR; FOOD CONTAMINATION; HUMAN; INCIDENCE; NEUROLOGIC DISEASE; NEUROTOXICITY; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; UNITED KINGDOM;

EID: 0032435141     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(98)90067-6     Document Type: Article

References (42)

1. 1. Martyn C N. Epidemiology. In: Williams AC, ed. Motor Neuron Disease. New York: Chapman & Hall Medical, 1994: 393-426.
2. 2. Juergens S M, Kurland L T, Okazaki H, Mulder D W. ALS in Rochester, Minnesota, 1925-1977. Neurology 1980; 30: 463-470.
3. 3. Kokmen E, Beard C M, Offord K P, Kurland L T. Prevalence of medically diagnosed dementia in a defined United States population: Rochester, Minnesota. Neurology 1989; 39: 773-776.
4. 4. Rajput A H, Offord K P, Beard C M, Kurland L T. Epidemiology of parkinsonism: incidence, classification and mortality. Ann Neurol 1984; 16: 278-282.
5. 5. Halliwell B. Reactive oxygen species and the central nervous system. J Neurochem 1992; 59: 1609-1623.
6. 6. Halliwell B. Antioxidants in human health and disease. Ann Rev Nutr 1996; 16: 33-50.
7. 7. Blass J P, Gibson G E. The role of oxidative abnormalities in the pathophysiology of Alzheimer's disease. Rev Neurol (Paris) 1991; 147: 513-525.
8. 8. Gurney M E, Pu H, Chiu A Y et al. Motor neuron degenerations that express a human Cu, Zn superoxide dismutase mutation. Science 1994; 264: 1772-1775.
9. 9. Shaw P J, Ince P G, Falkous G, Mantle D. Oxidative damage to protein in sporadic motor neuron disease spinal cord. Ann Neurol 1995; 38: 691-695.
10. 10. Jenner P, Olanow C W. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology (suppl) 1996; 47: S161-S170.
11. 11. Markesbery W R. Oxidative stress hypothesis in Alzheimer's disease. Free Rad Biol Med 1997; 23: 134-147.
12. 12. Tu P H, Gurney M E, Julien J P, Lee V M, Trojanowski J Q. Oxidative stress, mutant SOD1, and neurofilament pathology in transgenic mouse models of human motor neuron disease. Lab Invest 1997; 76: 441-456.
13. 13. Martensson A, Meister A. Glutathione deficiency decreases tissue ascorbate levels in newborn rats: ascorbate spares glutathione and protects. Proc Natl Acad Sci USA 1991; 88: 4656-4660.
14. 14. Meister A. Glutathione-ascorbic acid antioxidant system in animals. J Biol Chem 1994; 269: 9397-9400.
15. 15. Thanislass J, Reveendran M, Devraj H. Buthionine sulfoximine-induced glutathione depletion. Its effect on antioxidants, lipid peroxidation and calcium homeostasis in lung. Biochem Pharmacol 1995; 50: 229-234.
16. 16. Kosower N S, Kosower E M. The glutathione status of cells. Int Rev Cytol 1978; 54: 109-160.
17. 17. Lomaestro B M, Malone M. Glutathione in health and disease: pharmacotherapeutic issues. Ann Pharmacother 1995; 29: 1263-1273.
18. 18. Monaghan D T, Bridges R J, Cotman C. The excitatory amino acid receptors: their classes and distinct properties in the function of the central nervous system. Ann Rev Pharmacol Toxicol 1989; 29: 365-402.
19. 19. Gozlan H, Ben-Ari Y. NMDA receptor redox sites: are they targets for selective neuronal protection? Trends Pharm Sci 1995; 16: 368-374.
20. 20. Janaky R, Varga V, Jenei Z J, Saransaari P, Oja S S. Glutathione and glutathione derivatives: possible modulators of ionotropic glutamate receptors. In: Shaw C A, ed. Glutathione in the Nervous System. Washington, DC: Taylor & Francis, 1998: 163-196, ch. 8.
21. 21. Zangerle L, Cuenod M, Winterhalter K H, Do K Q. Screening of thiol compounds: depolarization-induced release of glutathione and cysteine from rat brain slices. J Neurochem 1992; 59: 181-189.
22. 22. Shaw C A, Pasqualotto B A, Curry K. Glutathione-induced sodium currents in neocortex. Neuroreport 1996; 7: 1149-1152.
23. 23. Bains J S, Shaw C A. Neurodegenerative disorders in humans: the role of glutathione in oxidative stress-mediated neuronal death. Brain Res Rev 1997; 25: 335-358.
24. 24. Lang C A, Naryshkin S, Schneider D L, Mills B J, Lindeman R D. Low blood glutathione levels in healthy aging adults. J Lab Clin Med 1992; 120: 720-725.
25. 25. Benzi G, Moretti A. Age- and peroxidative stress-related modifications of the cerebral enzymatic activities linked to mitochondria and the glutathione system. Free Rad Biol Med 1995; 19: 77-101.
26. 26. Griffith O W, Meister A. Potent and specific inhibition of glututhione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine). J Biol Chem 1979; 254: 7558-7560.
27. 27. Gallo J M, Brennan J, Hamilton T C et al. Time-dependent pharmacodynamic model for chemotherapy: population pharmacodynamic model for glutathione depletion following modulation by buthionine sulfoximine (BSO) in a phase I trail of melphalan and BSO. Cancer Res 1995; 55: 4501-4511.
28. 28. O'Dwyer P J, Hamilton T C, LaCreta E P et al. Phase I trail of buthionine sulfoximine in combination with melphalan in patients with cancer. J Clin Oncol 1996; 14: 249-256.
29. 29. Holt J A G. The glutathione cycle is the creative reaction of life and cancer. Cancer causes oncogenes and not vice versa. Med Hypotheses 1993; 40: 262-266.
30. 30. Backon J. Dementia in cancer patients undergoing chemotherapy: implications of free radical injury and relevance to Alzheimer disease. Med Hypotheses 1991; 35: 146-147.
31. 31. Griffith O W, Anderson M E, Meister A. Inhibition of glutathione biosynthesis by prothionine sulfoximine (S-n-propyl homocysteine sulfoximine), a selective inhibitor of γ-glutamylcysteine synthetase. J Biol Chem 1979; 254: 1205-1210.
32. 32. Broquist H P. Buthionine sulfoximine, an experimental tool to induce glutathione deficiency and ascorbate in their role as antioxidants. Nutr Rev 1992; 50: 110-111.
33. 33. Mellanby E. Diet and canine hysteria: experimental production by treated flour. Br Med J 1946; 4484: 885-887.
34. 34. Silver M L, Zevin S S, Kark R M, Johnson R E. Canine epilepsy caused by flour bleached with nitrogen trichloride (agene). I. Experimental method. Proc Soc Exp Biol Med 1947a; 66: 408-409.
35. 35. Campbell P N, Work T S, Mellanby E. Isolation of crystalline toxic factor from agenized wheat flour. Nature 1950; 165: 345-346.
36. 36. Silver M L. Canine epilepsy caused by flour bleached with nitrogen trichloride. IV. Histopathology. J Neuropath Exp Neurol 1949; 8: 441-445.
37. 37. Newell G W, Erickson T C, Gilson W E, Gershoff S N, Elvehjem C A. Studies on human subjects receiving highly agenized food materials. J Lab Clin Med 1949; 34: 239-245.
38. 38. Finch C E, Cohen D M. Aging, metabolism and Alzheimer disease: review and hypotheses. Exp Neurol 1997; 143: 82-102.
39. 39. Lynch D R, Dawson T M. Secondary mechanism in neuronal trauma. Curr Opin Neurol 1994; 7: 510-516.
40. 40. Seiler N. Is ammonia a pathogenetic factor in Alzheimer's disease? Neurochem Res 1993; 18: 235-245.
41. 41. Girard G, Giguere J F, Butterworth R F. Region-selective reductions in activities of glutamine synthetase in rat brain following portocaval anastomosis. Metab Brain Dis 1993; 8: 207-215.
42. 42. Silver M L, Johnson R E, Kark R M, Klein J R, Monahan E P, Zevin S S. White bread and epilepsy in animals. J Am Med Assoc 1947b; 135: 757-760.